STOCK TITAN
  1. Home
  2. News
  3. CRNX

Crinetics Pharmaceuticals Inc - CRNX STOCK NEWS

IMPACT
SENTIMENT
CRNX : Nasdaq
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
IMPACT
SENTIMENT
CRNX : Nasdaq
Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma
clinical trial
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
conferences
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
offering
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
offering
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
clinical trial
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
CRNX : Nasdaq
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
earnings
Stock CRNX logo
Crinetics Pharmaceuticals Inc
Nasdaq:CRNX

CRNX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About CRNX

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.